Nitrous oxide promotes hyperhomocysteinemia in levodopa treated rats
Department of Neurology
Analgesics, Non-Narcotic; Analysis of Variance; Animals; Catechols; Drug Interactions; Enzyme Inhibitors; Homocysteine; Hyperhomocysteinemia; Immunoassay; *Levodopa; Male; Nitriles; Nitrous Oxide; Random Allocation; Rats; Rats, Wistar
Nervous System Diseases | Neurology | Neuroscience and Neurobiology
BACKGROUND: This study investigated whether brief exposure to nitrous oxide (N(2)O) exacerbates levodopa-induced hyperhomocysteinemia, and if co-treatment with folate or entacapone could reduce total plasma homocysteine (tHcy) levels.
METHODS: Male Wistar rats (N=9 per group) were randomly treated with vehicle/N(2)O (GROUP 1), levodopa/nitrogen (group 2), levodopa/N(2)O (group 3), levodopa/N(2)O+folate (group 4), or levodopa/N(2)O+entacapone (group 5). tHcy was measured at 12 min, 4, 8, and 12 h after anesthesia.
RESULTS AND CONCLUSION: The combination of N(2)O-exposure and levodopa treatment significantly increased tHcy in rats. This hyperhomocysteinemia could be prevented by entacapone but not folate co-administration.
DOI of Published Version
Parkinsonism Relat Disord. 2007 Dec;13(8):524-7. Epub 2007 Jan 19. Link to article on publisher's site
Parkinsonism and related disorders
Henninger N, Wang Q, Okun JG, Schwab S, Krause M. (2007). Nitrous oxide promotes hyperhomocysteinemia in levodopa treated rats. Neurology Publications. https://doi.org/10.1016/j.parkreldis.2006.11.005. Retrieved from https://escholarship.umassmed.edu/neuro_pp/449